Clinical trial NCT03464201: Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GREKO III Study
Official title: Open Label Phase II Clinical Trial of Enzalutamide in Metastatic or Advanced Non-resectable Granulosa Cell Ovarian Tumors: GreKo III Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Ovarian Cancer
Lead sponsor: Grupo Español de Tumores Huérfanos e Infrecuentes
Sponsor class: OTHER
Collaborators: name: Astellas Pharma Inc
name: Apices Soluciones S.L.
First posted: 2018-03-13
Enrollment: 16
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The good tolerability profile of enzalutamide, the fact that the administration of steroids is not necessary and the impressive results achieved in prostate cancer, make this drug an ideal candidate to be tested in ovarian granulosa cancer, a tumor that could somehow be considered as "female prostate cancer".


Eligibility criteria: Inclusion Criteria:

* Patients who have given written informed consent
* Women aged 18 years or over
* Eastern Cooperative Oncology Group (ECOG) ≤ 1
* Diagnosis of histologically confirmed ovarian granulose carcinoma
* Availability of sufficient biopsy material for confirmation of the diagnosis by a centralized pathologist and determination of the mutation FOXL2402C→ G(C134W). If this material is not available, principal investigator of the study will confirm eligibility of the patient.
* Metastatic or unresectable disease
* Radiologically measurable disease. In case you there is not measurable disease, principal investigator of the study will confirm eligibility of the patient. - - Life expectancy ≥ 12 weeks
* Patients with adequate hepatic function, defined by: Aspartate transaminase (AST) and alanine aminotransferase (ALT) serum values ≤ 3 x upper limit of normal (except in the presence of metastasis in which case values ≤ 5 x upper limit of normal will be allowed), Total bilirubin values ≤ 1,5 x upper limit of normal
* Patients with adequate bone marrow function, defined by: Absolute neutrophil count ≥ 1.5 x 109 / L, Platelets ≥100 x 109/L, Hemoglobin ≥ 9 g/dL
* Patients with adequate renal function: serum creatinine ≤ 1,5 x upper limit of normal
* Absence of any disability to follow the study protocol
* Women childbearing potential who are sexually active, not undergoing hysterectomy or double adnexectomy, should follow the following contraceptive indications: Negative Pregnancy Test in serum or urine in the 72 hours before the start of treatment, use of a medically accepted method of contraception during: 2 months prior to the start of study treatment, during the study and up to 3 months after the last dose of treatment.

Exclusion Criteria:

* Patients with another primary tumor 2 years before beginning the drug under study, with the exception of adequately treated or totally surgically removed cervical carcinoma in-situ or basalioma or superficial bladder carcinoma
* Patients who have received radical radiotherapy ≤ 4 weeks prior to the start of study treatment or who have not recovered from toxicities of radiotherapy. Palliative radiation therapy for painful bone lesions bone is allowed up to 14 days prior to the beginning of the study treatment
* History of seizures or any conditions that may predispose to suffer them
* Current or previously treated brain metastases or disease leptomeningeal.
* Patients with cardiac insufficiency or heart disease clinically significant including any of the following: History or presence of uncontrolled severe ventricular arrhythmias, clinically significant resting bradycardia, any of the following diseases within 6 months prior to the start of the study drug -Myocardial infarction (MI), severe or unstable angina, coronary revascularization, congestive cardiac insufficiency (CCI), cerebrovascular accident (CVA), transient ischemic accident (TIA)-
* Patients with altered gastrointestinal function or with gastric disease that significantly alters the absorption of enzalutamide, such as for example: severe ulcer diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, extensive resection (\> 1m) of the small bowel or inability to swallow oral medication. The previous partial or total gastrectomy is not an exclusion criterion.
* Diagnosis of human immunodeficiency virus (HIV) infection.
* Pregnant or lactating women.
* Women of childbearing potential not using an effective contraceptive method. - Patients who do not want or can follow the study protocol.

Primary outcomes:
measure: Overall response rate (ORR)
timeFrame: Up to 6 months
Secondary outcomes:
measure: Clinical benefit rate
timeFrame: Up to 6 months
measure: Progression-free survival (PFS)
timeFrame: Up to 6 months
measure: Overall survival (OS)
timeFrame: Up to 6 months
measure: Incidence of Treatment-Emergent Adverse Events
timeFrame: Up to 6 months
Other outcomes:
Locations:
city: Barcelona
country: Spain
facility: Hospital de Mar
city: Córdoba
country: Spain
facility: Hospital Reina Sofia
city: Madrid
country: Spain
facility: Hospital Madrid Sanchinarro (CIOCC)
city: Madrid
country: Spain
facility: Hospital Universitario La Paz
city: Palma De Mallorca
country: Spain
facility: Hospital Son Llatzer
city: Pamplona
country: Spain
facility: Hospital de Navarra
city: Santiago De Compostela
country: Spain
facility: Complejo Hospitalario Universitario de Santiago
city: Valencia
country: Spain
facility: Hospital La Fe
Study officials:
affiliation: CIOCC (Hospital Universitario HM Sanchinarro)
name: Garcia-Donas, MD
role: PRINCIPAL_INVESTIGATOR
References: